Cargando…
Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis
BACKGROUND: To assess the safety and efficacy of sorafenib and sunitinib as first-line treatments for metastatic renal cell carcinoma (mRCC), to provide evidence-based support for clinical decision-making regarding rational drug use. METHODS: Until May 10, 2023, a comprehensive search was conducted...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10489528/ https://www.ncbi.nlm.nih.gov/pubmed/37682147 http://dx.doi.org/10.1097/MD.0000000000034983 |
_version_ | 1785103666674401280 |
---|---|
author | Li, Dailong Wan, Sha Li, Wanqiang Cheng, Chunlai Xu, Lu Gu, Peng |
author_facet | Li, Dailong Wan, Sha Li, Wanqiang Cheng, Chunlai Xu, Lu Gu, Peng |
author_sort | Li, Dailong |
collection | PubMed |
description | BACKGROUND: To assess the safety and efficacy of sorafenib and sunitinib as first-line treatments for metastatic renal cell carcinoma (mRCC), to provide evidence-based support for clinical decision-making regarding rational drug use. METHODS: Until May 10, 2023, a comprehensive search was conducted across PubMed, EMBASE, Cochrane Library, ClinicalTrials.gov, China National Knowledge Infrastructure, and Wanfang databases to identify clinical studies comparing sorafenib with sunitinib as first-line treatment for mRCC. The literature was screened, data extracted, and quality evaluated independently by 2 researchers. Meta-analysis was conducted using Revman5.4 software. RESULTS: A total of 3741 patients were enrolled in 20 studies. The meta-analysis results indicated that there were no significant differences in the 2- and 5-year progression-free survival (PFS) and overall survival (OS) rates between the sorafenib and sunitinib groups (P > .05). The disease control rate (DCR) was comparable between the 2 groups (P > .05), while the objective response rate (ORR) was higher in the sunitinib group (P = .03). However, subgroup analysis revealed no significant differences in ORR, DCR, 2- and 5-year PFS, and OS rates between sorafenib and sunitinib among both Asian populations as well as European and American populations (P > .05). In terms of drug-related adverse events, the incidence of grade ≥ 3 hypertension, leukopenia, neutropenia, thrombocytopenia, anemia, nausea and vomiting were significantly lower in the sorafenib group compared to the sunitinib group (P < .05). CONCLUSION: In the first-line treatment of mRCC, sorafenib exhibits comparable efficacy to sunitinib but with lower toxicity. |
format | Online Article Text |
id | pubmed-10489528 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-104895282023-09-09 Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis Li, Dailong Wan, Sha Li, Wanqiang Cheng, Chunlai Xu, Lu Gu, Peng Medicine (Baltimore) 5700 BACKGROUND: To assess the safety and efficacy of sorafenib and sunitinib as first-line treatments for metastatic renal cell carcinoma (mRCC), to provide evidence-based support for clinical decision-making regarding rational drug use. METHODS: Until May 10, 2023, a comprehensive search was conducted across PubMed, EMBASE, Cochrane Library, ClinicalTrials.gov, China National Knowledge Infrastructure, and Wanfang databases to identify clinical studies comparing sorafenib with sunitinib as first-line treatment for mRCC. The literature was screened, data extracted, and quality evaluated independently by 2 researchers. Meta-analysis was conducted using Revman5.4 software. RESULTS: A total of 3741 patients were enrolled in 20 studies. The meta-analysis results indicated that there were no significant differences in the 2- and 5-year progression-free survival (PFS) and overall survival (OS) rates between the sorafenib and sunitinib groups (P > .05). The disease control rate (DCR) was comparable between the 2 groups (P > .05), while the objective response rate (ORR) was higher in the sunitinib group (P = .03). However, subgroup analysis revealed no significant differences in ORR, DCR, 2- and 5-year PFS, and OS rates between sorafenib and sunitinib among both Asian populations as well as European and American populations (P > .05). In terms of drug-related adverse events, the incidence of grade ≥ 3 hypertension, leukopenia, neutropenia, thrombocytopenia, anemia, nausea and vomiting were significantly lower in the sorafenib group compared to the sunitinib group (P < .05). CONCLUSION: In the first-line treatment of mRCC, sorafenib exhibits comparable efficacy to sunitinib but with lower toxicity. Lippincott Williams & Wilkins 2023-09-08 /pmc/articles/PMC10489528/ /pubmed/37682147 http://dx.doi.org/10.1097/MD.0000000000034983 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | 5700 Li, Dailong Wan, Sha Li, Wanqiang Cheng, Chunlai Xu, Lu Gu, Peng Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis |
title | Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis |
title_full | Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis |
title_fullStr | Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis |
title_full_unstemmed | Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis |
title_short | Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis |
title_sort | sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: a systematic review and meta-analysis |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10489528/ https://www.ncbi.nlm.nih.gov/pubmed/37682147 http://dx.doi.org/10.1097/MD.0000000000034983 |
work_keys_str_mv | AT lidailong sorafenibexhibitslowertoxicityandcomparableefficacytosunitinibasafirstlinetreatmentformetastaticrenalcellcarcinomaasystematicreviewandmetaanalysis AT wansha sorafenibexhibitslowertoxicityandcomparableefficacytosunitinibasafirstlinetreatmentformetastaticrenalcellcarcinomaasystematicreviewandmetaanalysis AT liwanqiang sorafenibexhibitslowertoxicityandcomparableefficacytosunitinibasafirstlinetreatmentformetastaticrenalcellcarcinomaasystematicreviewandmetaanalysis AT chengchunlai sorafenibexhibitslowertoxicityandcomparableefficacytosunitinibasafirstlinetreatmentformetastaticrenalcellcarcinomaasystematicreviewandmetaanalysis AT xulu sorafenibexhibitslowertoxicityandcomparableefficacytosunitinibasafirstlinetreatmentformetastaticrenalcellcarcinomaasystematicreviewandmetaanalysis AT gupeng sorafenibexhibitslowertoxicityandcomparableefficacytosunitinibasafirstlinetreatmentformetastaticrenalcellcarcinomaasystematicreviewandmetaanalysis |